期刊文献+

浸润性乳腺癌超声征象与肿瘤雌激素受体、孕激素受体、人表皮生长因子受体-2表达的关系 被引量:4

Correlation of ultrasound findings with tumor biological markers ER,PR and HER-2 in invasive breast cancer
原文传递
导出
摘要 目的探讨乳腺癌超声征象与肿瘤分子生物学指标雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体-2(HER-2)之间的相关性。方法回顾性分析122例浸润性乳腺癌超声二维征象与肿瘤ER、PR及HER-2表达的相关性。结果本组病例ER阳性70例,PR阳性72例,HER-2过度表达38例。肿瘤形态不规则组ER及PR阳性率高于形态规则组,差异有统计学意义(P<0.05)。肿瘤边缘不光整、有毛刺或成角畸形组ER及HER-2阳性率高于边缘光整组,差异有统计学意义(P<0.05)。肿瘤内有钙化灶组ER、PR及HER-2表达阳性率均高于各自阴性组,差异均有统计学意义(P<0.05)。结论乳腺癌超声征象与ER、PR、HER-2的表达具有相关性,可在一定程度上反映乳腺癌ER、PR及HER-2的表达状态,为乳腺癌的术前辅助内分泌治疗和预后评估提供了一定的信息。 Objective To investigate whether invasive bteast cancer ultrasound features could be correlated with biological markers: estrogen receptor(ER),progesterone receptor(PR) and human epidermal growth factor receptor-2(HER-2).Methods We performed a retrospective review of the sonographical and biological features of women with invasive breast cancer who were admitted in our institute.Ultrasound findings(size,shape,boundary,echo pattern,echogenic halo,and presence of calcifications) of 122 breast cancers were analyzed and correlated with the tumor biological markers by univariate and multivariate logistic regression analyses.Results A total of 122 women were analysed.There were 70 cases with ER positive,72 cases with PR positive and 38 cases with HER-2 overexpression.ER and PR positive cancers displayed more frequently an irregular shape and more calcifications(P0.05).HER-2 positive cancers also displayed more calcifications as ER and PR did(P0.05).In univariate analysis,ER and HER-2 positive cancers had more frequently not circumscribed margins(P0.05).Conclusion Ultrasound pattern is correlated with tumor biological markers in invasive breast cancers and it may be useful for prediction of prognosis.
出处 《临床医学》 CAS 2010年第12期37-39,共3页 Clinical Medicine
关键词 乳腺肿瘤 超声检查 性激素受体 人表皮生长因子受体-2 Breast neoplasms Ultmsonography Sexual hormones receptor Human epidermal growth factor receptor-2
  • 相关文献

参考文献7

  • 1Tavassoli EF,Devilee P.WHO:Pathology & Genetics,Tumours of the breast and female genital organs[M].Lyon:IARC Press,2003:10.
  • 2Mired DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis [J]. Mod Pathol, 1998,11 (2) : 155 - 168.
  • 3Wolff AC,Hammond ME,Schwartz JN.et al.American Society of Clinical Oncoiogy/CoUege of American Pathologists guideline recommendations for Human Epidermal Growth Factor Receptor 2 testing in breast cancer[J].Arch Pathol Lab Med,2007,131(1):18-43.
  • 4Hong AS,Rosen EL,Soo MS,et al.BI-RADS for sonography:positive and negative predictive values of sonographic features[J].AJR Am J Roentgenol,2005,184(4):1260-1265.
  • 5Ildefonso C,Vazquez J,Guinea O,et al.The mammographic appearance of breast carcinomas of invasive ductal type:relationship with clinicopathological parameters,biological features and prognosis[J].Eur J Obstet Gynecol Reprod Biol,2008,136(2):224-231.
  • 6Nadine T,Yihong W,Laura CC,et al.Estrogen receptor positive breast cancers in BRCA1 mutation carriers:clinical risk factors and pathologic features[J].Breast Cancer Research,2010,12(2):104-113.
  • 7Seo BK,Pisano ED,Kuzimak CM,et al.Correlation of HER-2/neu overexpression with mammography and age distribution in primary breast carcinomas[J].Acad Radiol,2006,13(10):1211-1218.

同被引文献60

  • 1步宏,郑杰.美国临床肿瘤学会/美国病理学医师学院乳腺癌HER2检测指南简介[J].中华病理学杂志,2007,36(7):496-497. 被引量:24
  • 2盂庆春,刘芳,方少琼,等.乳腺增生病辩证分型与黄体期性激素水平的相关性研究[J].现代医学,2008,8(11):25-26.
  • 3Ross JS, Slodkowska EA, Symmans WF, et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalizedmedicine[J]. Oncologist,2009,14(4): 320-368.
  • 4Shi YX, Tan YT, Yuan ZY, et al. Comparison of overall survival between the early use and delayed use of trastuzumab therapy groups: a retrospective analysis of 128 patients with HER-2-positive advanced breast cancer[J]. Med Oncol,2012, 29(1) :39-47.
  • 5Untch M, Muscholl M, Tjulandin S, et al. First-line trastuzumab plus epirubicin and cyclophosphamidetherapy in patients with human epidermal growth factor receptor 2- positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubiein (HERCULES) trial[J]. J Clin Oncol,2010,28(9) :1473-1480.
  • 6Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positlve locally advanced breast cancer (the NOAH trial) : a randomised controlled superiority trial with a parallel HER2-negative cohort[J]. Lancet, 2010,375 (9712) : 377-384.
  • 7Ahn ER, Vogel CL. Dual HER2-targeted approaches in HER2-positive breast cancer[J]. Breast Cancer Res Treat, 2012,131(2) :371-383.
  • 8Siegel R, Naishadham D, JemaI A. Cancer statistics,2013 [ J ]. CA : a cancer journal for clinicians ,2013,63 ( 1 ) : 11 - 30.
  • 9Klapper LN, Kirchbaum MH, Sela M, et al. Biochemical and clini- cal implication of the ErbB/HER signaling network of growth fac- tor receptors[ J]. Adv Cancer Res,2000,77:25 - 79.
  • 10Klapper LN, Glathe S, Vaisman N, et al. The ErbB - 2/HER2 on- coprotein of human carcinomas may function solely as a shared co- receptor for multiple storma - derived growth factors [ J ]. Proc Natl Acad Sci, 1999,96 ( 9 ) :4995 - 5000.

引证文献4

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部